Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β‐estradiol

VM Jasonni; Jasonni VM; Carlo Bulletti; C Bulletti; S. Naldi; Elisabetta Di Cosmo; E Di Cosmo; Fabio Cappuccini; F Cappuccini; C Flamigni

doi:10.1016/0020-7292(92)90408-b

Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β‐estradiol

VM Jasonni, Jasonni VM, Carlo Bulletti, C Bulletti, S. Naldi, Elisabetta Di Cosmo, E Di Cosmo, Fabio Cappuccini, F Cappuccini, C Flamigni

International Journal of Gynecology & Obstetrics · 1992 · vol. 37(3) , pp. 235–236 · doi:10.1016/0020-7292(92)90408-b · PMID:1826278 · W2417735981

article OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by qwen3.7-flash, 2026-08-19 ⓘ

Nine cycles of oral cyproterone acetate and transdermal 17β-estradiol significantly improved hirsutism, acne, and seborrhea while decreasing plasma testosterone and dehydroepiandrosterone sulfate levels in twenty-four women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty-four hirsute women were treated with an inversal sequential scheme of cyproterone acetate, 50 mg/d by oral route from the 1st to the 15th day of the menstrual cycle, along with 100 micrograms/24 h of 17 beta-estradiol transdermally administered from days 1 to 21, for nine cycles at weekly intervals. The acne and seborrhea as well as hirsutism showed a significant improvement in all subjects studied. The plasma testosterone and dehydroepiandrosterone sulfate decrease from 1.5 +/- 1.3 ng/mL and 6.9 +/- 1.3 micrograms/mL to 0.5 +/- 0.03 ng/mL and 2.7 +/- 1.7 micrograms/mL, respectively. Similar values were observed in subjects with idiopathic hirsutism during the treatment. The metabolic parameters, as well as the plasma levels of sex hormone-binding globulin, appeared unaffected by the therapy. Furthermore, the luteinizing hormone and follicle-stimulating hormone secretion was strongly inhibited from the first cycle of treatment. In conclusion, considering the good clinical results and the avoidance of any hepatic effect, this association should be taken into account in the treatment of hirsutism, especially in case of oral estrogen intolerance.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism 1975

References (17)

Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism via openalex
doi:10.1016/b978-0-12-571126-5.50013-3 via openalex
doi:10.1111/j.1365-2362.1978.tb00822.x via openalex
doi:10.1210/jcem-47-3-581 via openalex
doi:10.1016/0378-5122(88)90062-x via openalex
doi:10.1016/0002-9378(83)90796-2 via openalex
doi:10.1016/0039-128x(83)90022-3 via openalex
W221483455 via openalex
W1965617734 via openalex
doi:10.1210/jcem-51-5-1107 via openalex
doi:10.1210/jcem-21-11-1440 via openalex
doi:10.1016/s0140-6736(69)91616-x via openalex
doi:10.1016/0021-9150(81)90093-9 via openalex
doi:10.1210/jcem-33-4-671 via openalex
W2418573623 via openalex
doi:10.3109/00016348609161484 via openalex
doi:10.1037/11774-004 via openalex

SciLite annotations

chemicals 10

cyproterone acetate estradiol cyproterone acetate estradiol testosterone dehydroepiandrosterone sulfate estrogen

organisms 1

noordeloos 2009062

Source provenance

crossref: last seen: 2026-06-25T06:33:51.166717+00:00
openalex: last seen: 2026-05-10T10:17:52.702552+00:00
scilite: last seen: 2026-05-18T04:26:01.642840+00:00
unpaywall: last seen: 2026-08-19T06:23:00.919175+00:00

License: CC0 · commercial use OK

[1] Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism 1975